期刊
PLANTA MEDICA
卷 84, 期 3, 页码 176-181出版社
GEORG THIEME VERLAG KG
DOI: 10.1055/s-0043-120447
关键词
Euphorbia pekinensis; Euphorbiaceae; polyphenols; diabetic complications; advanced glycation end-products; vessel dilation
资金
- Korea Institute of Oriental Medicine [K16270, K17270]
- National Research Council of Science & Technology (NST), Republic of Korea [K16270, K17270] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)
To identify active compounds in the roots of Euphorbia pekinensis for treatment of diabetic complications, an active column fraction from a 70% EtOH extract of E. pekinensis root was purified by preparative reversed-phase high-performance liquid chromatography, leading to the isolation of a new ellagic acid derivative, 3,3-di- O -methylellagic acid 4- O -(6- O -galloyl)- -D-galactopyranoside ( 1 ), along with three known compounds, geraniin ( 2 ), 3,3-di- O -methylellagic acid 4- O - -D-xylopyranoside ( 3 ), and ellagic acid 3,3-dimethyl ether ( 4 ). The structure of the new compound was established by extensive spectroscopic studies and chemical evidence. The inhibitory effects of isolated compounds 1 - 4 on advanced glycation end-products (AGEs) formation were examined. All compounds exhibited considerable inhibition of AGEs formation and IC (50) values of 0.41-12.33 mu M, compared with those of the positive controls aminoguanidine (IC (50) =1122.34 mu M) and quercetin (IC (50) =27.80 mu M). In addition, the effects of 2 and 4 on the dilation of hyaloid-retinal vessels induced by high glucose (HG) in larval zebrafish were investigated; both compounds significantly reduced the HG-induced dilation of hyaloid-retinal vessels relative to the HG-treated control group.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据